Updated data from the TNBC cohort of the TROPION-PanTumor01 phase 1 trial of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan featured as oral presentation at SABCS New data from the TROPION-PanTumor01
Drug combination shows revolutionary results in extending life for tough-to-treat breast cancer go.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from go.com Daily Mail and Mail on Sunday newspapers.
Eric P Winer elected ASCO President for term starting in June 2022 miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
(1)
Agendia and Roche evaluate BluePrint s stratification of HER2+ early breast cancer patients treated with adjuvant pertuzumab Agendia, Inc., a world leader in precision oncology for breast cancer, today announced data from the APHINITY trial in a poster spotlight discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).
The poster, titled
Prediction of benefit from adjuvant pertuzumab by BluePrint RNA sequencing in the APHINITY trial, outlines data from an exploratory analysis of the Phase 3 study that randomized 4,805 patients with histologically centrally confirmed HER2+ early breast cancer into two arms, one which received standard adjuvant chemotherapy and trastuzumab plus pertuzumab, and one which received standard adjuvant chemotherapy and trastuzumab plus placebo, for one year. The analysis was conducted in collaboration with Roche Pharmaceuticals.